Mastzellstabilisator

Mastzellstabilisator is a class of pharmaceutical agents used in the treatment of allergic reactions and conditions involving mast cell stabilization. These medications work by preventing the degranulation of mast cells, which are immune cells that release inflammatory mediators such as histamine, leukotrienes, and prostaglandins during allergic responses. By stabilizing the mast cell membrane, mastzellstabilisators help reduce the severity and frequency of allergic symptoms, including hay fever, allergic conjunctivitis, and some forms of asthma.

Common mastzellstabilisators include cromolyn sodium and nedocromil. Cromolyn sodium is often administered via inhalation for asthma or as eye drops for allergic conjunctivitis. Nedocromil is primarily used as a treatment for allergic asthma and is available in inhaler form. These agents are generally well tolerated, with mild side effects such as throat irritation or cough. They are considered prophylactic rather than symptomatic treatments, meaning they are most effective when used regularly to prevent allergic episodes rather than during acute attacks.

Mastzellstabilisator drugs are often prescribed as part of an overall allergy management plan, potentially combined with antihistamines or corticosteroids. Their mechanism of action specifically targets the prevention of mast cell degranulation, distinguishing them from other allergy medications that primarily block the effects of released mediators.

Overall, mastzellstabilisators are an important component in the management of allergic diseases, especially for patients who require long-term prophylaxis. Ongoing research continues to explore their applications and potential benefits in other immune-mediated conditions.